Lobular breast cancer can be more difficult to treat than some other types of breast cancer. Dr Patrick Derksen is looking at whether combinations of palbociclib and gedatolisib could stop this type of breast cancer progressing, giving women the best possible chance of survival.

Professor Madalena Tarsounas is testing if combining drugs talazoparib and chlorambucil could be more effective at killing cancer cells, and less toxic to healthy cells, than using these drugs individually.

PARP inhibitors are a new class of drugs that work well for patients who have changes in their BRCA genes. Professor Claudio Sette and his team want to understand more about how these drugs work and whether they could benefit more patients with triple negative breast cancer.

Professor Agnes Noel is testing combinations of drugs that stop two different proteins from working to see if they offer potential as a future treatment for patients with triple negative breast cancer.

Professor Simak Ali and Dr Lesley-Ann Martin are investigating how proteins called CDKs play a part in cancer’s resistance to palbociclib – a drug used to treat oestrogen receptor positive (ER+) secondary breast cancer. He is exploring whether blocking a protein called CDK7 could be a new way to treat tumours that have become resistant to palbociclib.

Professor Jukka Westermarck is finding new ways to predict which existing drugs will be most effective for triple negative breast cancers. He is investigating how different combinations of altered proteins in cancer cells affect their response to a number of experimental drugs.